Clinical trial
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
NCT00146588 · Craig A. Bunnell, MD, MPH, Other · Completed
Key facts
| NCT number | NCT00146588 |
|---|---|
| Title | Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer |
| Official title | A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women With Stage I/II/IIIA Breast Cancer |
| Lead sponsor | Craig A. Bunnell, MD, MPH, Other |
| Collaborators | Dana-Farber Cancer Institute Massachusetts General Hospital Brigham and Women's Hospital Beth Israel Deaconess Medical Center Pharmacia Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Epirubicin, Capecitabine |
| Enrollment | 55 |
| Start date | Apr 1, 2002 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Sep 7, 2005 |
| Last update posted | Mar 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: